Fujifilm and Takeda to jointly commercialize iPS cell-derived cardiomyocytes

Fujifilm's owns iPS cell technology and sophisticated engineering technology c through its US subsidiary, Cellular Dynamics International, and Takeda Pharmaceutical does joint research (T - CiRA) with Kyoto University iPS cell research institute (CiRA). Both companies will jointly develop and commercialize regenerative medical products using iPS cell derived cardiomyocytes.

Source: Fujifilm news release, February 8, 2018

Request a quote for deeper information from

© 2018 Window to Japan - Bio 4 Business - Imprint